Sector News

Sanofi starts on viral vector facility as its R&D focus shifts to gene therapies

October 23, 2019
Life sciences

Sanofi is playing catch-up in gene therapy, but new CEO Paul Hudson is taking quick steps to close the gap. A reorganization of the R&D unit is intended to pivot the drugmaker toward immuno-oncology drugs and gene therapies.

And to hasten the transition, the company is retrofitting a vaccine plant in France into a gene therapy manufacturing operation.

A spokesman Monday confirmed Sanofi is preparing teams at its Lyon-Gerland site to work on vector-based gene therapies. Hudson spoke about the project in an interview with BioPharma Dive. The drugmaker expects the facility to be operational a year from now.

Sanofi has invested about €25 million in the Lyon-Gerland site over the last five years. In 2013, the drugmaker struck a deal with France’s Transgene to share the cost of a €10 million facility there to manufacture Transgene’s immuno-oncology therapies.

The Lyon vaccine facility is being retrofitted even as Sanofi this summer reworked its gene therapy partnership with Voyager Therapeutics. Sanofi dumped two programs it has started with Voyager, and now the two will develop adeno-associated virus capsids —the protein shells of the virus—for the delivery of gene therapies. Sanofi gets the exclusive option to use these capsids to deliver treatments for up to two non-CNS diseases.

The project also comes as Sanofi has been upgrading other parts of its manufacturing network for the future. Last week, it opened a new biologics plant in Massachusetts that it considers its prototype plant of the future. In the digitally enabled manufacturing facility, all manufacturing stages are controlled through analytical processes that are forecast to avoid variations.

Plant operators also have access to data analytics or augmented reality solutions that can help them make real-time decisions and adjustments. He said the remade plant is 80 times more productive while also reducing energy use and emissions by 80%.

As for gene therapy production, Sanofi is following other companies such bluebird bio and Gilead’s Kite Pharma in building viral vector manufacturing facilities to serve their gene therapy or CAR-T development programs, which are much further along than Sanofi’s.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach